REACT Study
Start date:Nov 2019 End date:
Dec 2019 Co-ordinated by:
Lumira Dx Main trial site:
RIE, Edinburgh
A performance evaluation study designed to assess the precision and accuracy of the Lumira DX point of care (POC) and C-Reactive (CRP) assay as an aid in the detection and evaluation of infection, tissue injury and inflammatory disorders.
In the emergency department (ED), CRP is tested in patients presenting with a variety of symptoms as an aid the detection and evaluation of infection, tissue injury or inflammatory disorders.
Primary objective – To determine the performance of the LumiraDx POC CRP assay when compared to the Siemens Dimension reference method in patients with symptoms of infection, tissue injury and inflammatory disorders.
Sample size – 50 participants over a duration of approximately 4 weeks.
Chief Investigator
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Local PI
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Research Team
Julia Grahamslaw
Lead Research Nurse
Nicky Freeman
Senior Research Nurse
More EMERGE Trials
Assisting in identifying patients with Humeral shaft fractures in the ED by screening.
Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.
HU-FIX Trial
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.